Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

L.A. McKeown

October 07, 2022

Presentation TCT 2022

TCT 642: Threading the Needle - A Challenging Case of TAVR in a Patient with an LVOT Protruding Balloon-Expandable TMVR

Presenter: Giorgio Medranda

September 19, 2022

Presentation TCT 2022

Trans-Apical Mechanical Splitting of the Anterior Mitral Leaflet to Prevent LVOT Obstruction Before TMVR: FIH Experience With the SHORTCUT Device

Presenter: Paolo Denti

September 19, 2022

Presentation TCT 2022

CT Imaging for TMVR Planning: Predictors of LVOT Obstruction and Implications for Device Selection

Presenter: Philipp Blanke

September 19, 2022

Presentation TCT 2022

LVOT Obstruction: Prediction Models and Emerging Prevention Techniques

Presenter: Mayra Guerrero

September 18, 2022

Presentation TCT 2022

Outcomes of Mitral Regurgitation Patients Screen Failed for LVOT Obstruction Treated Using Altavalve

Presenter: Vinayak N. Bapat

September 18, 2022

Presentation Interventional Complications 2022

LVOT obstruction post TMVR

Presenter: Adam Greenbaum

July 15, 2022

Presentation TVT 2022

LVOT Obstruction Post-TMVR: Predictors, Prevention, and Post-interventional Management

Presenter: Vinayak N. Bapat

June 10, 2022

Presentation TVT 2022

Mitral Transcatheter Edge-to-Edge Repair for Dynamic LVOT Obstruction

Presenter: Tim Hinohara

June 10, 2022

Presentation TVT 2022

#2 Case Resolution: Acute LVOT Obstruction Post-TMVR

Presenter: Adam Greenbaum

June 08, 2022

Presentation TVT 2022

#2 Case Presentation: Acute LVOT Obstruction Post-TMVR

Presenter: Adam Greenbaum

June 08, 2022

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

News Conference News STS 2022

CHOICE-MI: TMVR Mortality Much Lower With Newer Transseptal Devices

Todd Neale

February 03, 2022

Presentation Miami Valves 2022

Lampoon Transcatheter Mitral Valve Replacement

Presenter: Harris Khan

February 03, 2022

Advertisement

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

TCT 642: Threading the Needle - A Challenging Case of TAVR in a Patient with an LVOT Protruding Balloon-Expandable TMVR

Trans-Apical Mechanical Splitting of the Anterior Mitral Leaflet to Prevent LVOT Obstruction Before TMVR: FIH Experience With the SHORTCUT Device

CT Imaging for TMVR Planning: Predictors of LVOT Obstruction and Implications for Device Selection

LVOT Obstruction: Prediction Models and Emerging Prevention Techniques

Outcomes of Mitral Regurgitation Patients Screen Failed for LVOT Obstruction Treated Using Altavalve

LVOT obstruction post TMVR

LVOT Obstruction Post-TMVR: Predictors, Prevention, and Post-interventional Management

Mitral Transcatheter Edge-to-Edge Repair for Dynamic LVOT Obstruction

#2 Case Resolution: Acute LVOT Obstruction Post-TMVR

#2 Case Presentation: Acute LVOT Obstruction Post-TMVR

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

CHOICE-MI: TMVR Mortality Much Lower With Newer Transseptal Devices

Lampoon Transcatheter Mitral Valve Replacement

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content